ERBB2 and breast carcinoma: As immunotherapy has shown activity and durable clinical benefit in patients with PD‐L1‐positive, trastuzumab‐resistant HER2‐positive breast cancer, further studies of the levels of TILs, the PD‐L1 status, and clinical benefits of immunotherapy on the HER2 mutations population are needed.